Chronic kidney disease with congestive heart failure increases the risk of kidney failure due to dyes used during angiography or stent surgery. The Benephit Delta system is a catheter-based medical device that delivers specific drugs and other therapeutic agents directly to the renal artery. The system is capable of simultaneous selective administration of the two renal arteries, using only one catheter. The primary purpose of the system was to target kidney therapy as an alternative to systemic intravenous drug therapy for renal insufficiency associated with congestive heart failure.
This procedure was recently performed in a male patient at the New York-Presbyterian Hospital in the United States, who underwent vasodilation to treat severe coronary occlusion. Five stents were placed in his coronary arteries, which required the use of large doses of dye. The Benephit Delta system is used to deliver a drug (Fenodon) to the kidneys of the patient directly through the renal artery to increase blood flow.
The patient did not develop life-threatening radiographic contrast nephropathy. Cardiovascular doctors estimate that approximately 20% of patients undergoing coronary interventions can benefit from the treatment of radiation contrast nephropathy.
FlowMedica introduces anti-surgical renal failure equipment
FlowMedica developed the Benefit Delta system. This is a new device designed to prevent renal insufficiency in patients with congestive heart failure during coronary surgery.